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Introduction
Vienna provided a delightful forum for the 21st European
Workshop for Rheumatology Research (EWRR), March
1–4, 2001, hosted by Professor Josef Smolen. In addition
to a reception with the mayor and governor of Vienna, a
‘Viennese evening,’ and a premeeting dinner and guided
tour hosted by world-reknowned figurative painter Adolf
Frohner, the program consisted of some novel and insight-
ful presentations by a multitude of arthritis researchers.
Participants in the meeting were from Europe, Asia, the
Middle East, and the United States, demonstrating that
the ‘European’ EWRR meeting is gaining increasing
prominence in the worldwide rheumatology community.
The meeting also featured cutting-edge talks from scien-
tists working in industry, highlighting the increasing inter-
action between academicians and biopharmaceutical
scientists. The author apologizes that only a subset of
studies is presented and that the sessions on ‘Connective
tissue and bone remodeling’ and ‘New aspects on patho-
genesis and therapy’ are not reported because of incom-
plete attendance by the author. This year’s meeting was
the first to schedule concurrent workshops, precluding
reporting of all areas of interest.
Novel technologies
The meeting opened with a series of six lectures describ-
ing new techniques. Like other areas of medical science,
rheumatology is undergoing rapid transition to a field dom-
inated by powerful new technologies. These are likely to
replace the traditional methods used to diagnose
rheumatic disease, to identify novel therapeutic targets,
and to elucidate the pathogenesis of autoimmunity.
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The central dogma of ‘medical’ cell biology is that DNA is
transcribed into RNA, which is translated into protein,
which is the target of therapeutic agents. It is protein that
governs cell structure and function, and a dominant theme
of the meeting was that human autoimmune disease is
manifested at the level of protein expression. Klaus
Wilgenbus (Vienna, Austria) reviewed current methods
used to perform transcriptional profiling, including the use
of ‘spotted’ DNA microarray technology and commercially
available DNA chips. An application of microarrays was
elegantly demonstrated in a later poster presentation by
U Ungethüm (Berlin, Germany; P45), in which DNA
microarray data from synovial tissue derived from healthy
controls (HC) or from patients with osteoarthritis (OA) or
rheumatoid arthritis (RA) were compared. These results
were then further compared with those obtained using a
PCR-based amplification (amplicon) technique. Potentially
interesting molecules found to be upregulated (in RA vs
HC) included megakaryocyte-stimulating factor, tumor
necrosis factor (TNF)-a, cathepsin B, and tissue inhibitor
of metalloproteinases (TIMP) 3, as well as (RA vs OA)
natural-killer-cell protein NKp58, ribosomal proteins, and
collagen. Interestingly, the results found varied with the
technique used, highlighting the fact that not all transcrip-
tional profiling methods are created equal.
In the next presentation, the author (PJU, Stanford Univer-
sity, USA) described work performed by William Robinson
(in collaboration with Lawrence Steinman), in which
autoantigen microarrays containing hundreds of diverse
antigens including proteins, peptides, ribonucleoproteins,
enzyme complexes, and nucleic acids were spotted and
detected by serum autoantibodies on microscope slides.
Major autoantigens were detectable in a high-throughput
format, including common antigenic targets in systemic
lupus erythematosus, scleroderma, RA, myositis, primary
biliary cirrhosis, mixed-connective-tissue disease, and Sjö-
gren’s syndrome. These arrays should prove useful for
performing multiplex serum autoantibody profiling of many
human autoimmune diseases and also of autoimmunity in
animal models.
Three lectures then described unique approaches to the
development of therapeutic agents for treatment of
autoimmune disease. ‘SELEX’ (systematic evolution of
ligands by exponential enrichment) is a method used to
identify oligonucleotides, ligands or ‘aptamers’. Renée
Schroeder (Vienna) described SELEX studies, in which
libraries of RNA ‘aptamers’ were screened to identify
unique RNA sequences capable of binding a ligand of
interest. The approach is similar in concept to identifying a
monoclonal antibody. Such ligands include amino acids,
cofactors, proteins, antibiotics, and other therapeutics.
RNA aptamers are amenable to chemical modifications
that might allow them to be used directly as therapeutic
agents in clinical medicine, with the potential to revolutionize
drug discovery in much the same way that monoclonal-
antibody therapies currently used in clinical rheumatology
practice have done. Manfred Auer (Vienna) reported on
studies at Novartis using ‘AIDA’ nanoscreening technol-
ogy, an on-bead screening assay that allows fluorescent
detection of drug-binding to candidate targets, followed
by rapid structural decoding. Finally, Ernst Wagner
(Vienna) reviewed advances in naked DNA technology
and the use of retroviruses, adenoviruses, and adeno-
associated viruses to encode immunoregulatory proteins
such as IL-1 receptor antagonist, IL-4, IL-10, and a TNF-
receptor immunoglobulin Fc fusion protein. Although not
discussed by Dr Wagner, DNA vaccine technology has
also recently been applied to deliver autoantigens as toler-
izing agents and will certainly be expanded in scope
during the next decade.
Antigens and antibodies in rheumatoid
arthritis
Since their identification nearly 40 years ago, antiperinu-
clear factor and antikeratin antibodies had been all but for-
gotten before being rediscovered in the 1990s in the
laboratories of Walther van Venrooij (Nijmegen, the
Netherlands) and Guy Serre (Toulouse, France). The dom-
inant B cell epitope has been definitively identified as one
containing citrulline residues, formed by enzymatic deimi-
nation of the amino acid arginine. The precise citrulline-
containing antigen that may be responsible for driving the
synovitis in RA remains elusive. Guy Serre presented data,
published soon after the meeting, identifying a candidate
citrullinated antigen [1]. His laboratory purified proteins
from synovial tissue and identified two molecules, of
66 kDa and 70 kDa, respectively, that reacted with
antiperinuclear factor on western blots. Surprisingly, the
proteins were identified as the a and b chains of fibrin. In
contrast, TJ Smeets and colleagues (Nijmegen, the
Netherlands; P4) presented a poster in which they were
unable to demonstrate differential binding of anticitrulline
antibodies to synovium in patients with RA vs controls.
Whether the a and b chains of fibrin represent the anti-
gens driving the autoimmune response in RA is an intrigu-
ing possibility that will require further investigation.
A number of posters and discussions described the utility
of clinical tests for RA that are based on the above discov-
eries. I Hromadenikova (Prague, Czech Republic; P1) pre-
sented data suggesting that antikeratin antibody may be
useful in the diagnosis of juvenile rheumatoid arthritis,
while J Vencovsky (Prague; P2) discussed preliminary
data regarding the prediction of erosive disease. Three
groups described studies using different substrates and
different methods in analyzing serum from fairly large pop-
ulations of patients with arthritis. The results (summarized
in Table 1) are of great importance as these diagnostic
tests gain increasing acceptance in clinical labs through-
out Europe and (hopefully) the United States.c
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Christophe Benoist updated experiments performed in
collaboration with Diane Mathis using their K/BXN mouse
model for RA. The details of this interesting model, in
which antibodies directed against the protein glucose-6
phosphate isomerase contribute to disease pathogenesis,
have been reviewed recently in this journal by Hugh
McDevitt [2]. Four unpublished observations were noted
by these investigators and presented by Dr Benoist. First,
the disease is heterogeneous and frequently asymmetric
in presentation, with only certain joints (even within the
same limb) becoming involved. Second, antibodies and
complement are detectable in the intimal synovial layer.
Third, experiments using knockout mice have demon-
strated a requirement for the activating receptor FcgRIII
and components of the alternative pathway of complement
activation. Finally, highly preliminary studies in humans
have identified serum antibodies directed against glucose-
6 phosphate isomerase in 52% of patients with inflamma-
tory arthritides, including RA and systemic lupus
erythematosus, but in only 6% of healthy controls.
Two other poster discussions generated significant inter-
est because of their relation to stress responses. S Hayer
and colleagues (Vienna; and Athens, Greece; P11)
described studies demonstrating upregulation of the RA
autoantigen hnRNP-A2/RA33 in joints of RA patients, and
in TNF-a transgenic mice. Surprisingly, the molecule,
which is predominantly nuclear in localization, was also
present in the cytoplasm of RA synovial cells, particularly
the macrophages of the lining layer and the fibroblasts of
the sublining layer. U Neuhaus-Steinmetz and colleagues
(Berlin, Germany; Ghent, Belgium; Bad Liebenwerda,
Germany; P13) identified the stress protein BiP as a novel
autoantigen in RA. Antibodies were found in 63% of a
cohort of 400 patients with RA by western blot analysis,
but in only 3.5% of patients with other rheumatic diseases
and in less than 1% of healthy controls. These results are
in agreement with the recently reported findings of Corri-
gal, Panayi, and their colleagues [3].
Cytokine signaling and autoimmunity
The previous section described advances in understand-
ing the role played by antigen in driving diseases such as
RA. However, blockade of ‘downstream’ effectors — inhibi-
tion of inflammatory cytokines — has taken center stage in
the treatment of arthritis and inflammatory bowel disease.
One session of the meeting described advances in this
area. Marc Feldmann (London, UK; L17) provided an
overview of cytokine blockade in arguably the most inter-
esting presentation of the conference. Professor Feld-
mann challenged the role of T cells in RA (i.e. as important
or innocent bystanders). In RA, TNF-a production is T-cell
dependent, is secreted by macrophages (and perhaps
other cells), and is a ‘rate-limiting’ molecule. Thus there
exists a clear reason to block the actions of TNF. T cells
can be differentially regulated or activated, e.g. in an
Available online http://arthritis-research.com/content/3/4/237
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.antigen-receptor-specific manner (via TCR/CD28 stimula-
tion) and in an antigen-independent fashion (via inter-
leukins such IL-6, and TNF). Unfortunately, blockade of the
TNF pathway has the potential to inhibit host defense as
well as preventing systemic inflammation. This prediction
has been fulfilled by a significant increase in cases of reac-
tivation tuberculosis in patients treated with TNF antago-
nists, particularly in European patients. Professor Feldmann
described the work of B Foxwell, who has explored selec-
tive inhibition of cytokine-receptor signaling pathways (e.g.
IL-6, IL-2, TNF, and others) that may allow prevention of the
synovial inflammatory response without compromising host
immunity. These include compounds such as Wortmannin
and Ly290402 (PI-3 kinase inhibitors) and overexpression
of the natural NF-kB inhibitor, I-kB.
The work of N Busso and colleagues (Lausanne and
Geneva, Switzerland; P23) described the surprising
finding that mice deficient in leptin and its receptor are
significantly less sensitive to collagen-induced arthritis
than are wild type animals, as assessed by histology, lym-
phocyte proliferation assays, and technetium-99 scanning
of joints. This result is perhaps less surprising when one
considers that leptin and its receptor are homologous to
the respective cytokine/receptor pairs IL-6 and IL-11. John
O’Shea (Bethesda, MD, USA) presented data in which his
group has dissected the JAK/STAT signaling pathway. His
studies have identified JAK3 as a potential therapeutic
target, as well as P38 mitogen-activated protein kinase
(MAPK). A MAPK inhibitor has been developed that
blocks the production of interferon g and possibly prevents
the phosphorylation of STAT4.
Apoptosis and autoimmunity
LA Casciola-Rosen and colleagues have published a
number of important studies over the past decade impli-
cating apoptosis in connective tissue diseases (reviewed
[4]). Presentations by K Nishioka (Kawasaki, Japan; L14)
and B Sauter (Erlangen, Germany; L15) of largely pub-
lished work underscored the importance of developing a
better understanding of apoptosis in RA and other dis-
eases. Factors governing lymphocyte and synoviocyte
apoptosis, as well as processing and presentation of
apoptotic material by antigen-presenting cells including
dendritic cells, will continue to be key areas of research.
Guido Kroemer (Villejuif, France; L16) presented elegant
studies, in press in the journal Nature, exploring mecha-
nisms involved in caspase-independent death. Apoptosis-
inducing factor, a mitochondrial protein that translocates
to the cytoplasm and nucleus in response to certain death
stimuli, plays a central role in this process. This factor pro-
motes chromatin peripheralization and condensation.
Using an in vitro embryogenesis model, Kroemer showed
that the factor is required for progression from the morula
to the blastula stage, because a subset of the morula cells
are unable to undergo apoptosis, which is a requirement
for formation of the blastula cavity. AIF is required for large-
scale DNA fragmentation (as opposed to internucleosomal
DNA cleavage mediated by caspase-activated DNase, and
unlike cytochrome c, AIF’s function is clearly independent
of caspases. An important take-home point of these
studies is that many of the in vitro measures currently used
in rheumatology research to ‘define’ an apoptotic cell rely
on indirect detection of activated caspases, e.g. via DNA
fragmentation or identification of proteolytic fragments of
caspases or their target substrate proteins. The apoptotic
cell phenotype now clearly requires redefinition.
Summary
Major advances in technology now drive how we
approach questions in immunology, particularly in analyz-
ing complex data sets commonly encountered in
genomics and proteomics studies. Active areas of investi-
gation include development of novel technologies, identifi-
cation of elusive target antigens for RA and other
diseases, dissection of signaling pathways connecting the
lymphocyte cell surface with the nucleus, and exploration
of new avenues for therapeutic interventions. The EWRR
represents a forum for many European and nonEuropean
scientists to present high-quality research findings. Arthri-
tis researchers from around the globe should be strongly
encouraged to attend future meetings, beginning with the
22nd EWRR in Leiden in 2002.
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